Document is current
Any future updates will be listed below
-
Authors
Marelli, Giulia
Morina, Nicolò
Puccio, Simone https://orcid.org/0000-0003-4007-4365
Iovino, Marta
Pandini, Marta
Portale, Federica
Carvetta, Mattia
Mishra, Divya
Diana, Elisabetta
Meregalli, Greta
Paraboschi, Elvezia
Cibella, Javier
Peano, Clelia
Basso, Gianluca
De Simone, Gabriele
Camisaschi, Chiara
Magrini, Elena
Sartori, Giulio
Karimi, Elham
Colombo, Piergiuseppe
Lazzeri, Massimo https://orcid.org/0000-0002-4411-3715
Casale, Paolo
Morosi, Lavinia
Martano, Giuseppe https://orcid.org/0000-0002-5963-4580
Asselta, Rosanna
Bonavita, Eduardo
Matsunami, Hiro
Bertoni, Francesco https://orcid.org/0000-0001-5637-8983
Walsh, Logan https://orcid.org/0000-0001-8771-2577
Lugli, Enrico https://orcid.org/0000-0002-1964-7678
Di Mitri, Diletta https://orcid.org/0000-0002-9626-4259
- License Information
-
More Information
Article History
Received: 21 March 2024
Accepted: 15 May 2025
First Online: 30 June 2025
Competing interests
: E.L. received research funding from Bristol Myers Squibb unrelated to this study and consulting fees from Swarm Therapeutics, Menarini, Amgen, Pfizer and BioLegend. F.B. has received institutional research funds from ADC Therapeutics, Bayer AG, BeiGene, Floratek Pharma, Helsinn, HTG Molecular Diagnostics, Ideogen AG, Idorsia Pharmaceuticals Ltd., Immagene, ImmunoGen, Menarini Ricerche, Nordic Nanovector ASA, Oncternal Therapeutics and Spexis AG; consultancy fees from BIMINI Biotech, Floratek Pharma, Helsinn, Immagene, Menarini and Vrise Therapeutics; advisory board fees to the institution from Novartis. F.B. has also provided expert statements to HTG Molecular Diagnostics and has received travel grants from Amgen, Astra Zeneca and iOnctura. H.M. has received royalties from Chemcom, research grants from Givaudan and consultant fees from Kao. The remaining authors declare no competing interests.
